View:     View:
tid Target Cancers General Effect on Target
Name
Source
Type

TREM1 promotes tumor progression, immunosuppression, and resistance to therapy by activating tumor-infiltrating myeloid cells.
sTREM-1 Serum soluble triggering receptor expressed on myeloid cells-1.
High levels of sTREM-1 were observed in 50% of breast cancer, 33.3% of Small Cell Lung carcinoma (SCLC), 26.7% of colorectal cancer and 13.3% of Non Small Cell Lung Carcinoma (NSCLC) patients.




(Will delete Record if Target field = "Delete")
 Home